Optical Coherence Tomography Correlates Of Clinical And Imaging Outcomes In Early Multiple Sclerosis (P2.254)

OBJECTIVE:We aimed to study the association between changes in time-domain(TD) optical coherence tomography(OCT) outcomes and brain magnetic resonance imaging (MRI) or clinical outcomes in early multiple sclerosis (MS). BACKGROUND:The lack of surrogate outcomes of disability progression has limited the development of neuroprotection proof-of-concept trials. DESIGN/METHODS:Patients with relapsing-remitting MS within 12 months of onset were enrolled in a neuroprotection study of riluzole versus placebo as an add-on to weekly interferon beta-1a for up to 3 years. Clinical measures included Symbol Digit Modalities Test, Expanded Disability Status Scale, MS Functional Composite and low contrast letter acuity(LCLA). MRI outcomes included SIENAX normalized measurements [brain parenchymal volume, normal-appearing white and grey matter volumes] and percent brain volume changes measured by SIENA.OCTs (Stratus, Zeiss) were performed annually and included peripapillary retinal nerve fiber layer (RNFL) and radial macular volume. Mixed model regression and Spearman correlation measured time trends and associations between OCT and clinical and MRI outcomes. RESULTS:Forty-three patients were enrolled within 7.52 ± 4.93 months of disease onset (72% female, mean age: 36 ± 9.32, 97% white). There was a weak correlation between RNFL and LCLA (r=0.3, p=0.08) and T1and T2 lesion volumes (r= -0.4, p=0.02) at baseline. No other correlations were found between TD-OCT and clinical and imaging measures at baseline. Baseline MV and RNFL did not predict longitudinal changes in any of the clinical or imaging outcomes (p>0.05). There were also no associations between longitudinal changes in TD-OCT and clinical outcomes; however, changes in total RNFL were associated with percent brain volume change (SIENA) (p=0.02). CONCLUSIONS:TD-OCT measures do not appear to correlate strongly with clinical outcomes in this early MS trial whereas RNFL changes correlated some with brain volume changes. This may reflect the limited reproducibility of TD-OCT but may also be due to limited follow-up time and sample size. Study Supported by:National MS Society, MS International Federation, Nancy Davis foundation, study drug and interferon beta-1a from Sanofi Aventis and Biogen Idec. Disclosure: Dr. Maghzi has nothing to disclose. Dr. Revirajan has nothing to disclose. Dr. Julian has received personal compensation for activities with Genentech Inc. as an employee. Dr. Spain has nothing to disclose. Dr. Mowry has received research support from Teva Neuroscience. Dr. Liu has nothing to disclose. Dr. Marcus has received personal compensation for activities with Biogen Idec. Dr. Marcus has received research support from Biogen Idec. Dr. Jin has nothing to disclose. Dr. Green has received personal compensation for activities with Novartis, Prana Bioscience, Acorda Therapeutics, Roche Diagnostics Corp., and Biogen Idec. Dr. McCulloch has nothing to disclose. Dr. Pelletier has received personal compensation for activities with Teva Neuroscience, Genentech Inc., Biogen Idec as a speaker and advisory board member, and activities with Bayer Pharmaceuticals Corp. and Synarc as a consultant. Dr. Pelletier has received research support from Biogen Idec. Dr. Waubant has received personal compensation for activities with Roche Diagnostics Corporation, Biogen Idec, Sanofi-Aventis Pharmaceuticals Inc., Genzyme Corporation, and Novartis.